BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

James Mazzo Appointed Executive Chairman of Neurotech


8/6/2013 8:09:30 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CUMBERLAND, R.I., Aug. 6, 2013 /PRNewswire/ -- Neurotech Pharmaceuticals, a biotechnology company developing sight-saving therapies for chronic retinal disease, announced today that James Mazzo was appointed the company's Executive Chairman. Mazzo, a long time leader in the ophthalmic industry, is the former CEO of Abbott Medical Optics (AMO), is an Operating Partner at Versant Ventures and was recently named Chairman and CEO of AcuFocus, a Versant portfolio company.

(Logo: http://photos.prnewswire.com/prnh/20130806/NE59269LOGO)

As Executive Chairman, Mazzo will engage with the Neurotech team to advance the Company's novel technology platform through the clinical development stage toward market availability.

"Neurotech's technology is truly groundbreaking and I am confident it will bring improved therapy to serious retinal diseases such as wet and dry age-related macular degeneration, and macular telangiectasia diseases that ultimately cause blindness," said James Mazzo.

Neurotech's patented core technology platform, Encapsulated Cell Technology (ECT), is a genetically engineered implant that enables the continuous delivery of protein drugs directly into the vitreous of the eye. The Company has demonstrated that a single living ECT implant can treat a diseased retina for two years or more, thereby eliminating the need for monthly injections, the conventional approach to treating retinal disease. ECT systems can produce all classes of modern biotherapeutic drugs, including peptides, hormones, monoclonal antibodies, antibody fragments and next generation alternative scaffolds. As a robust technology platform, ECT can be adapted to also generate protein drugs targeting uveitis, glaucoma and other ophthalmic indications.

"I admire Jim's commitment to and extensive accomplishments in the ophthalmic world. We are honored to have him help lead our company as we advance Neurotech into the next phase of growth," said Ted Danse, President and CEO of Neurotech.

Jim Mazzo's 35-year career in the healthcare industry includes seven years as Chairman, President and CEO of Advanced Medical Optics (AMO), which was sold to Abbott Labs in 2009 for $2.8 billion. He was previously with Allergan for over 20 years in a variety of expanding roles, working and living in the U.S., England, Italy and Canada. He led the spinoff of AMO from Allergan in 2002, expanding the business into a $1 billion industry-leading, publicly-traded corporation. Most recently, he has served as Senior Vice President, Abbott Laboratories and President, Abbott Medical Products.

William J. Link, PhD, Managing Director at Versant Ventures and a Neurotech board member, said, "Jim's talents are tremendously applicable to Neurotech. We look forward to working together to further Neurotech's promising technology in the treatment of retinal diseases and help people retain their sight."

About Neurotech Pharmaceuticals, Inc.

Neurotech is developing sight-saving therapeutics for the treatment of chronic retinal diseases. Utilizing its transformational technology, Encapsulated Cell Technology (ECT), Neurotech is developing intraocular implants that provide controlled, sustained and long-term delivery of therapeutic proteins to the back of the eye, thereby overcoming a major obstacle in the treatment of retinal disease. The Company's lead ECT-based product candidates include NT-503 for the treatment of wet AMD (Phase 2), and Renexus® (NT-501) for the treatment of Macular Telangiectasia (pre-Phase 2). To learn more, please visit www.neurotechusa.com.

SOURCE Neurotech USA



Hey, check out all the research scientist jobs. Post your resume today!


Read at BioSpace.com

Neurotech
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES